NCT05825781View on ClinicalTrials.gov

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

January 22, 2024

Study Completion Date

September 30, 2024

Conditions

Healthy Men

Interventions

DRUG

Pertuzumab

i.v.

DRUG

Perjeta®

i.v.

Trial Locations (1)

Unknown

"Central Clinical Hospital RZD-Medicina", Moscow

All Listed Sponsors

lead

Mabscale, LLC

INDUSTRY